South San Francisco, United States
Neuron23, founded in 2018, is a clinical-stage biotechnology company based in the United States. The company is pioneering advancements in precision medicine, specifically targeting Parkinson’s disease driven by hyperactive LRRK2. By integrating cutting-edge science with human genetics and its proprietary drug discovery and biomarker platform, Neuron23 is using machine learning and AI to significantly enhance therapeutic development.
With a strong commitment to transforming treatment methods and improving patient outcomes, Neuron23 has garnered substantial financial backing. Its most recent financing round, a $100.00M Series C investment on March 30, 2022, was led by notable investors such as Kleiner Perkins, Redmile Group, Acorn Bioventures, and SoftBank Vision Fund, among others. This investment underlines the confidence in Neuron23’s innovative approach and its potential to make a significant impact in the biotechnology space.
